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Background: Peripheral artery disease (PAD) represents atherosclerotic disease and is a risk factor for death in
peritoneal dialysis (PD) patients, who tend to show an atherogenic lipid profile. In this study, we investigated the
relationship between lipid profile and ankle-brachial index (ABI) as an index of atherosclerosis in PD patients with
controlled serum low-density lipoprotein (LDL) cholesterol level.
Methods: Thirty-five PD patients, whose serum LDL cholesterol level was controlled at less than 120mg/dl, were
enrolled in this cross-sectional study in Japan. The proportions of cholesterol level to total cholesterol level
(cholesterol proportion) in 20 lipoprotein fractions and the mean size of lipoprotein particles were measured using
an improved method, namely, high-performance gel permeation chromatography. Multivariate linear regression
analysis was adjusted for diabetes mellitus and cardiovascular and/or cerebrovascular diseases.
Results: The mean (standard deviation) age was 61.6 (10.5) years; PD vintage, 38.5 (28.1) months; ABI, 1.07 (0.22).
A low ABI (0.9 or lower) was observed in 7 patients (low-ABI group). The low-ABI group showed significantly higher
cholesterol proportions in the chylomicron fraction and large very-low-density lipoproteins (VLDLs) (Fractions 3–5) than
the high-ABI group (ABI>0.9). Adjusted multivariate linear regression analysis showed that ABI was negatively
associated with serum VLDL cholesterol level (parameter estimate=−0.00566, p=0.0074); the cholesterol
proportions in large VLDLs (Fraction 4, parameter estimate=−3.82, p=0.038; Fraction 5, parameter estimate=−3.62,
p=0.0039) and medium VLDL (Fraction 6, parameter estimate=−3.25, p=0.014); and the size of VLDL particles
(parameter estimate=−0.0352, p=0.032).
Conclusions: This study showed that the characteristics of VLDL particles were associated with ABI among PD
patients. Lowering serum VLDL level may be an effective therapy against atherosclerosis in PD patients after the
control of serum LDL cholesterol level.
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Peripheral artery disease (PAD) is frequently observed
among patients with end-stage renal disease (ESRD) [1]. A
cross-sectional study showed that the prevalence of PAD
was 27.4% in 343 PD patients [2]. In accordance with the
Trans-Atlantic Inter-Society Consensus 2 for the manage-
ment of PAD (TASC2), PAD is diagnosed using the ankle-
brachial index (ABI) [3].
PAD is associated with increased mortality and cardiac
mortality among hemodialysis patients [4,5]. A single-
center cohort study of 153 PD patients showed that a
decrease in ABI increased the risk of death [6]. PAD
represents atherosclerotic disease. In the Reduction of
Atherothrombosis for Continued Health registry, PAD
was observed with polyvascular disease [7]. The risk fac-
tors for PAD are diabetes mellitus (DM), age, and serum
albumin, triglyceride (TG) and serum cholesterol levels
[2,6,8]. Although PAD is prevalent in PD patients, it
remains to be clarified which factors affect the progres-
sion of atherosclerosis and the development of PAD in
PD patients.
Dyslipidemia is considered as one of the risk factors
for PAD in TASC2 [3]. PD patients tend to have athero-
genic lipid profiles, such as high levels of total cholesterol,
LDL cholesterol (LDL-C), TG, and small dense LDL-C
with a low level of high-density lipoprotein cholesterol
(HDL-C) [9]. The kidney disease outcomes quality ini-
tiative (K/DOQI) showed that 78.6% of PD patients need
treatment for dyslipidemia [10]. The Japanese Society of
Nephrology and the Japanese Society for Dialysis Therapy
guidelines recommend that serum LDL-C level should be
maintained at less than 120 mg/dl [11,12]. However, the
effect of lipid profiles on atherosclerosis has not been clari-
fied in PD patients with controlled serum LDL-C levels.
We previously established a method, namely, high-
performance gel permeation chromatography (HPGPC)
that can separate lipoproteins into 20 fractions on the
basis of differences in particle size [13,14]. The HPGPC
method measures all lipoprotein subclasses in a single
analysis from a very small amount of whole serum or
plasma in a very short time. We successfully applied this
technique to show that the visceral fat area is positively
correlated with cholesterol levels in very-low-density
lipoprotein (VLDL) and low-density lipoprotein (LDL)
subclasses, but negatively with those in large and high-
density lipoprotein (HDL) subclasses in male subjects
with visceral fat syndrome or obesity, and that cardio-
vascular disease patients had a significantly higher chol-
esterol levels in small VLDL, small LDL, and very small
LDL subclasses, but a lower cholesterol level in large
HDL [13, 15].
In this study, we investigate the effects of lipid profile
at subclass levels and the size of lipoproteins on ABI as
a marker of atherosclerosis in the peripheral artery inPD patients with serum LDL-C level controlled at less
than 120 mg/dl by HPGPC.
Methods
Study design and study population
This is a cross-sectional study of PD patients (more than
20 years of age) treated at Tokyo Kyosai Hospital, Tokyo,
Japan, and JA Toride Medical Center, Toride, Japan, from
October 2011 to December 2011, which was approved
by the local human research ethics committee of Tokyo
Kyosai Hospital, and JA Toride Medical Center. Written
informed consent was obtained from each patient. Patients
were eligible for inclusion in this study if they were able
to stably undergo continuous ambulatory PD or auto-
mated PD as outpatients. They were treated with dialy-
sates containing dextrose (Dianeal-NPD-2, -NPD-4 1.5
or 2.5, Baxter Japan, Tokyo; Mid Peric or Mid Peric L
135 or 250, Terumo, Tokyo) and a dialysate with or
without icodextrin (Extraneal, Baxter Japan, Tokyo). We
adhered to the Japanese Society for Dialysis Therapy
guidelines for treatment by PD [16]. Dyslipidemia was
diagnosed on the basis of the criteria of the Japan
Atherosclerosis Society [17]. A high LDL-C level was
treated in accordance with the evidence-based practice
guideline 2009 for the treatment of chronic kidney disease
of the Japanese Society of Nephrology and clinical guide-
lines for the evaluation and treatment of cardiovascular
complications in hemodialysis patients of the Japanese
Society for Dialysis Therapy [11,12]. Serum LDL-C level
was maintained at less than 120mg/dl by administration
of statin. Fibrates, ezetimibe, probucol, resins, other lipid
lowering drugs and antioxidant drugs were not used in the
patients of this study. We excluded patients who had malig-
nant diseases, infectious diseases, or severe liver diseases.
Data
Patient demographics including age; gender; comorbid
conditions such as DM, hypertension, and dyslipidemia;
statin use; and history of cardiovascular and/or cerebro-
vascular diseases (CVDs) were obtained from the medical
records of the patients at each hospital. None of the pa-
tients were administered ezetimibe or fibrates. ABI was
measured using an analyzer, Vascular Screening System
VaSera VS-1500N (Fukuda Denshi Co., Tokyo, Japan).
ABI was calculated using the ratio of systolic blood
pressure in the ankles to systolic blood pressure in the
arms, which was derived by taking the mean of the right
and left ratios. We defined ABI to be low on the basis
of the criteria of TASC2 [3]. The patients who had a
low ABI (0.9 or lower) were classified into the low-ABI
group and others into the high-ABI group. Blood sam-
ples were obtained from each patient after a 12 hour
overnight fasting with an overnight dwell of dialysate
containing 2.5% dextrose. Serum samples were dispensed
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each hospital, one for measurement of apolipoprotein
B at SRL Inc., Tokyo, Japan, and one for HPGPC at
Skylight Biotech Inc., Akita, Japan. The blood samples
for HPGPC were frozen at −80°C immediately after their
collection until use. Routine serum biochemistry was
carried out by standard methods at each hospital. Albumin-
corrected serum calcium level was calculated as follows:
albumin-corrected serum calcium level (mg/dL) = measured
serum calcium level (mg/dL) + (4.0 - serum albumin
level [g/dL]), when the serum albumin level was less
than 4.0 g/dL. Intact parathyroid hormone (PTH) level was
measured using an immunoassay system (ARCHITECT
Intact PTH, Abbott Japan Co., Chiba, Japan). Non-HDL-C
level was calculated as the difference between total choles-
terol and HDL-C levels. Apolipoprotein B was measured
using an immunoassay kit (Apolipoprotein B; Sekisui
Medical Co., Tokyo, Japan). Lipoprotein fractions were
analyzed by HPGPC as previously described [13,14]. In
brief, 4 μL aliquots of whole serum samples were injected
into columns and what was continuously monitored at
550 nm after an online enzymatic reaction. Cholesterol
level and the proportion of cholesterol level in each
lipoprotein fraction to total cholesterol level (cholesterol
proportion) were calculated mathematically with modified
Gaussian curve fitting to resolve overlapping peaks: chy-
lomicrons (CMs) [Fraction 1 (F1) and F2], large VLDL
(F3-F5), medium VLDL (F6), small VLDL (F7), LDL (F8),
medium LDL (F9), small LDL (F10), very small LDL (F11-
F13), very large HDL (F14-F15), large HDL (F16), medium
HDL (F17), small HDL (F18), and very small HDL (F19-
F20) [13,14]. Considering the diameters of LDL particles,
medium, small, and very small LDLs (F9 - F13) are con-
sistent with the classification of small dense LDL particles
by Okazaki et al. and Austin et al. [13,18]. The cholesterol
and TG proportions in F1 and F2 were combined and
treated as those in the CM fraction. The mean sizes of
very-low-density lipoprotein cholesterol (VLDL-C), LDL-C,
and HDL-C particles were measured by HPGPC using a
calculation based on the defined size of lipoprotein
particles and the cholesterol proportion in lipoprotein
fractions [13,19].
Statistical analyses
Normally distributed variables are presented as mean and
standard deviation; otherwise, the median and interquar-
tile range are presented. For parameters not normally dis-
tributed, intergroup comparisons were performed using
the chi-square test, t test, and Mann–Whitney U test as
appropriate. For parameters not normally distributed,
natural logarithm values were considered in tests that
require normally distributed variables after the tests
of their normality: the natural logarithm values of CM
cholesterol (CM-C) level [log(CM)] and TG level [log(TG)].Univariate linear regression analysis was carried out to
determine the relationships of ABI with the clinical and
biochemical characteristics of patients. Multivariate linear
regression analysis, which was adjusted for factors that
were previously selected among the patient characteristics,
were carried out to identify the factors that were inde-
pendently associated with ABI. The relationships between
the size of lipoprotein particles and serum cholesterol
and TG levels or the cholesterol proportion in lipopro-
tein fractions were evaluated using Pearson’s correlation
coefficients or Spearman’s rank correlation coefficient as
appropriate. These analyses were conducted using SAS,
version 9.2 (SAS, Inc., North Carolina, US). Statistical
significance was defined as p<0.05.
Results
Patient characteristics
Thirty-five patients on PD were included as subjects for
analysis. Of these, 28 showed high ABI levels (high-ABI
group) and seven patients showed low ABI levels (low-ABI
group). The patient demographics including biochemical
data are shown in Table 1. Only one patient had an ABI
(1.61) higher than 1.4. The prevalences of DM and history
of CVD were higher in the low-ABI group, and the serum
glucose levels of the low-ABI group were higher than
those of the high-ABI group. Hemoglobin A1c were mea-
sured among DM patients; low-ABI group, 6.3±0.9%; high-
ABI group, 6.2±0.6%. The distributions of cholesterol and
TG levels in lipoprotein classes were examined between
the high- and low-ABI groups (Table 2). The VLDL-C
and TG levels in the low-ABI group were higher than
those in the high-ABI group.
Cholesterol proportions in lipoprotein fractions and ABI
The cholesterol proportions in different lipoprotein
fractions are shown in Figure 1. In large VLDLs (F3-F5),
the cholesterol proportions in the low-ABI group were
higher than those in the high-ABI group (F3, p=0.011;
F4, p=0.038; F5, p=0.032). In small HDL (F18), the chol-
esterol proportions in the low-ABI group were margin-
ally lower than those in the high-ABI group (p=0.088).
Univariate linear regression analysis showed that DM
and CVD were associated with ABI (DM, parameter
estimate=−0.19, p=0.0077; CVD, parameter estimate=−0.19,
p=0.022). ABI was not associated with age; gender; BMI;
hypertension; statin use; icodextrin use; serum creatin-
ine, albumin, albumin-corrected serum calcium, phos-
phate, and intact PTH levels; and albumin-corrected serum
calcium-phosphate product. Univariate linear regression
analysis of lipid levels showed that ABI was negatively as-
sociated with log(CM) and VLDL-C level, and multivariate
linear regression analysis adjusted for DM and CVD also
showed that ABI was negatively associated with log(CM)
and VLDL-C level (Table 3).
Table 1 Clinical and biochemical characteristics of patients
All High-ABI group Low-ABI group p
N (%) 35 28 7
Male (%) 28 (80) 22 (78.6) 6 (85.7) 0.66
Age 61.6 ± 10.5 60.8 ± 10.7 64.9 ± 9.9 0.36
Height (cm) 163.0 ± 9.6 163.8 ± 9.9 159.8 ± 8.5 0.33
Weight (kg) 60.8 ± 11.1 61.6 ± 12.1 57.4 ± 4.6 0.38
BMI 22.8 ± 3.4 22.9 ± 3.5 22.7 ± 3.3 0.91
DM (%) 15 (42.9) 9 (32.1) 6 (85.7) 0.009*
Hypertension (%) 31 (88.6) 26 (92.9) 5 (71.4) 0.15
Dyslipidemia (%) 17 (48.6) 14 (50.0) 3 (42.9) 0.74
Statin use (%) 12 (34.3) 9 (32.1) 3 (42.9) 0.60
CVD (%) 9 (25.7) 4 (14.3) 5 (71.4) 0.003*
Icodextrin use (%) 18 (51.4) 14 (50.0) 4 (57.1) 0.74
Creatinine (mg/dl) 10.4 ± 3.1 10.4 ± 3.4 10.4 ± 1.4 0.97
Albumin (g/dl) 3.3 ± 0.4 3.3 ± 0.4 3.1 ± 0.4 0.40
Glucose (mg/dl) 114.7 ± 32.9 108.9 ± 24.4 141.5 ± 53.7 0.025*
Albumin-corrected serum calcium (mg/dl) 9.8 ± 0.7 9.7 ± 0.8 9.9 ± 0.7 0.52
Phosphate (mg/dl) 5.0 ± 0.9 5.0 ± 0.9 4.9 ± 0.9 0.84
Intact PTH (pg/mL) 178.4 ± 22.1 195.9 ± 237.8 91.3 ± 53.6 0.22
121.0 (65.0, 221.0) 132.0 (76.0, 225.0) 65.0 (57.5, 112.0)
PD vintage (months) 38.5 ± 28.1 36.6 ± 30.1 46.0 ± 17.3 0.44
D/P Cr 0.63 ± 0.14 0.64 ± 0.12 0.55 ± 0.19 0.21
ABI 1.07 ± 0.22 1.15 ± 0.13 0.72 ± 0.14 0.0001*
Values are expressed as mean ± standard deviation. Intact PTH is expressed as median and interquartile range. The values are compared between the groups by
the chi-square test, t-test and Mann–Whitney U test as appropriate. *, p<0.05.
Abbreviations: ABI, ankle-brachial index; High-ABI group, group of patients with high ABI (ABI>0.9); Low-ABI group, group of patients with low ABI (0.9 or low);
BMI, body mass index; DM, diabetes mellitus; CVD, cardiovascular and/or cerebrovascular disease; PTH, parathyroid hormone; PD, peritoneal dialysis; D/P Cr,
dialysate/plasma creatinine ratio.
Table 2 Serum lipid levels
All High-ABI group Low-ABI group p
Total cholesterol level (mg/dl) 182.0 ± 35.5 183.2 ± 37.5 177.1 ± 27.9 0.69
CM cholesterol level (mg/dl) 0.96 ± 1.97 0.57 ± 0.48 2.54 ± 4.17 0.75
0.42 (0.22, 1.05) 0.39 (0.22, 0.97) 0.49 (0.32, 3.81)
VLDL cholesterol level (mg/dl) 35.51 ± 15.54 33.78 ± 14.9 42.43 ± 17.1 0.19
LDL cholesterol level (mg/dl) 92.01 ± 27.75 93.30 ± 29.0 86.84 ± 23.1 0.59
HDL cholesterol level (mg/dl) 53.46 ± 21.20 55.50 ± 22.3 45.33 ± 14.5 0.26
Triglyceride level (mg/dl) 132.39 ± 71.60 123.40 ± 40.31 168.36 ± 140.90 0.10
118.95 (89.72, 153.11) 118.42 (94.98, 146.28) 130.06 (55.12, 256.53)
Apolipoprotein B level (mg/dl) 88.57 ± 21.32 87.82 ± 23.30 91.57 ± 11.41 0.68
Non-HDL cholesterol level (mg/dl) 128.48 ± 36.17 127.65 ± 39.50 131.80 ± 19.39 0.79
Values are expressed as mean ± standard deviation. CM cholesterol and triglyceride levels are expressed as median and interquartile range. The values are
compared between the groups by the t-test and Mann–Whitney U test as appropriate.
Abbreviations: ABI, ankle-brachial index; High-ABI group, group of patients with high ABI (ABI>0.9); Low-ABI group, group of patients with low ABI (0.9 or low);
CM, chylomicron; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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Figure 1 Cholesterol proportions in different lipoprotein fractions to total cholesterol level in low-ABI group compared with those in
high-ABI group. Average proportion of cholesterol level in each lipoprotein fraction to total cholesterol level is indicated in the graph. The values are
compared between the groups by the t-test and Mann–Whitney U test as appropriate. *, p<0.05. Abbreviations: proportion, average of the proportion
of cholesterol level in each lipoprotein fraction to total cholesterol level; High-ABI group, group of patients with high ABI (ABI>0.9); Low-ABI group,
group of patients with low ABI (0.9 or low); CM, chylomicron; F3-20, Fractions 3–20.
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proportion in lipoprotein fractions showed that ABI was
negatively associated with large VLDL (F3-F5) and medium
VLDL (F6) and positively associated with medium HDL
(F17), small HDL (F18), and very small HDLs (F19 and
F20) (Table 4). After adjustment for DM and CVD, ABI
was still associated with the cholesterol proportions in the
large VLDLs, medium VLDL, and the medium HDL.
Sizes of lipoprotein particles
The size of VLDL particles in the low-ABI group was
larger than that in the high-ABI group (Table 5). TheTable 3 Relationships between ABI and serum lipid levels
Univariate
Parameter estimate
Total cholesterol level (mg/dl) −0.000189 (0.00106)
Log(CM) −0.0701 (0.0250)
VLDL cholesterol level (mg/dl) −0.00547 (0.00222)
LDL cholesterol level (mg/dl) −0.000251 (0.00135)
HDL cholesterol level (mg/dl) 0.00316 (0.00168)
Log(TG) −0.151 (0.0770)
Apolipoprotein B level (mg/dl) −0.00232 (0.00171)
Non-HDL cholesterol level (mg/dl) −0.00127 (0.00101)
Relationships between ABI and serum lipid levels were evaluated by univariate or m
expressed as parameter estimates (standard deviation). *, p<0.05.
Abbreviations: Univariate, univariate linear regression analysis; multivariate, multivar
cholesterol level (mg/dl); VLDL, very-low-density lipoprotein; LDL, low-density lipopr
triglyceride level (mg/dl); DM, diabetes mellitus; CVD, cardiovascular and/or cerebronegative relationship between the size of VLDL particles
and ABI was observed after the adjustment for DM and
CVD (Table 6).
The size of VLDL particles was positively associated
with CM-C, VLDL-C, and TG levels, and negatively as-
sociated with HDL-C level (Table 7). The size of VLDL
particles was positively associated with the cholesterol
proportions in the CM, large VLDLs (F3-F5), medium
VLDL (F6), and very small LDL (F12), and negatively
associated with those in large LDL (F8) and large and
medium HDLs (F16 and F17) (Table 8). The size of LDL
particles was negatively associated with the cholesterolMultivariate
p Parameter estimate p
0.86 −0.00104 (0.00095) 0.28
0.0084* −0.0588 (0.0230) 0.016*
0.019* −0.00566 (0.00197) 0.0074*
0.85 −0.00106 (0.00118) 0.38
0.069 0.00206 (0.00152) 0.18
0.059 −0.130 (0.0679) 0.065
0.18 −0.00289 (0.00147) 0.058
0.22 −0.00167 (0.000874) 0.065
ultivariate linear regression analysis adjusted for DM and CVD. The values are
iate linear regression analysis; log(CM), natural logarithm value of chylomicron
otein; HDL, high-density lipoprotein; log(TG), natural logarithm value of
vascular disease.
Table 4 Relationship between ABI and the proportion of cholesterol level in each lipoprotein fraction
Univariate Multivariate
Class Subclass Fraction Parameter estimate p Parameter estimate p
CM F1 + F2 −4.13 (2.09) 0.056 −2.05 (1.99) 0.31
VLDL Large VLDL F3 −8.72 (3.36) 0.014* −5.62 (3.24) 0.92
F4 −4.99 (1.90) 0.013* −3.82 (1.76) 0.038*
F5 −4.26 (1.22) 0.0014* −3.62 (1.16) 0.0039*
Medium VLDL F6 −3.26 (1.43) 0.030* −3.25 (1.24) 0.014*
Small VLDL F7 −3.99 (3.03) 0.20 −4.11 (2.58) 0.12
LDL Large LDL F8 −0.383 (1.195) 0.75 −0.554 (1.034) 0.60
Medium LDL F9 0.0471 (0.870) 0.96 −0.162 (0.756) 0.83
Small LDL F10 −0.185 (1.353) 0.89 −0.122 (1.168) 0.92
Very small LDL F11 −1.21 (4.07) 0.77 −1.95 (3.51) 0.58
F12 −4.47 (11.57) 0.70 4.98 (10.36) 0.63
F13 8.75 (30.99) 0.78 7.44 (26.75) 0.78
HDL Very large HDL F14 −22.23 (28.83) 0.45 −13.71 (25.22) 0.59
F15 2.40 (1.78) 0.19 1.96 (1.54) 0.21
Large HDL F16 1.09 (0.59) 0.075 1.00 (0.51) 0.059
Medium HDL F17 3.68 (1.25) 0.0059* 3.06 (1.11) 0.0099*
Small HDL F18 5.36 (2.14) 0.017* 3.73 (1.97) 0.068
Very small HDL F19 12.48 (6.07) 0.048* 7.06 (5.72) 0.23
F20 58.56 (25.94) 0.031* 45.23 (23.00) 0.058
Relationships between ABI and the proportion of cholesterol level in each lipoprotein fraction were evaluated by univariate or multivariate linear regression
analysis adjusted for DM and CVD. The values are expressed as parameter estimates (standard deviation). *, p<0.05.
Abbreviations: Univariate, univariate linear regression analysis; multivariate, multivariate linear regression analysis; CM, chylomicron; VLDL, very-low-density
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; F1-20, Fraction 1–20; DM, diabetes mellitus; CVD, cardiovascular and/or
cerebrovascular disease.
Table 5 Sizes of lipoprotein particles
All High-ABI group Low-ABI group p
VLDL (nm) 40.19 ± 2.09 39.83 ± 1.79 41.62 ± 2.70 0.041*
LDL (nm) 25.26 ± 0.34 25.28 ± 0.32 25.20 ± 0.43 0.58
HDL (nm) 10.85 ± 0.35 10.85 ± 0.35 10.85 ± 0.34 0.99
Values are expressed as mean ± standard deviation. The values are compared
between the groups by t-test. *, p<0.05.
Abbreviations: ABI, ankle-brachial index; High-ABI group, group of patients with
high ABI (ABI>0.9); Low-ABI group, group of patients with low ABI (0.9 or low);
VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HDL,
high-density lipoprotein.
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associated with that in small VLDL (F7) (Table 8). The
size of HDL particles was negatively associated with
VLDL-C and TG levels (Table 7). The size of HDL parti-
cles was negatively associated with the cholesterol pro-
portions in large VLDLs (F4 and F5) and medium VLDL
(F6) (Table 8).
Discussion
In this study, we identified the relationships between
ABI and lipid profiles in PD patients by HPGPC. There
has been no detailed report of lipid profiles in PD patients
with controlled serum LDL-C levels. ABI was negatively
associated with VLDL-C level. We were able to determine
that the cholesterol proportions in VLDLs were higher in
the low-ABI group than in the high-ABI group, and that
ABI was negatively associated with VLDL-C level, choles-
terol proportions in the large and medium VLDLs and the
size of VLDL particles. Serum TG level was positively
associated with the sizes of VLDL particles and negatively
associated with those of LDL and HDL. The relationship
between the size of VLDL particles and the cholesterol
proportion in the very small LDL fraction was observed.
The size of LDL particles was negatively associated withthe cholesterol proportion in the large VLDLs, and the
size of HDL particles was negatively associated with the
cholesterol proportion in the large and medium VLDLs.
CM transports dietary TG from the gut to the liver
and peripheral tissue in the exogenous pathway of lipo-
protein metabolism. VLDL is produced by the liver and
serves as a vehicle for the delivery of endogenous lipids
to the peripheral tissue in the endogenous pathway of
lipoprotein metabolism. In this study, we found that the
patients in the low-ABI group tended to show high chol-
esterol proportions in the VLDLs, and that cholesterol
proportions in the VLDLs were associated with ABI in
PD patients. It has been reported that, in PD patients,
Table 6 Relationships between ABI and sizes of lipoprotein particles
Univariate Multivariate
Parameter estimate p Parameter estimate p
VLDL (nm) −0.0464 (0.0160) 0.0067* −0.0352 (0.0156) 0.032*
LDL (nm) 0.0317 (0.109) 0.77 0.00181 (0.0950) 0.99
HDL (nm) 0.0642 (0.108) 0.55 0.0834 (0.0923) 0.37
Relationships between ABI and the sizes of lipoprotein particles were evaluated by univariate or multivariate linear regression analysis adjusted for DM and CVD.
The values are expressed as parameter estimates (standard deviation). *, p<0.05.
Abbreviations: Univariate, univariate linear regression analysis; multivariate, multivariate linear regression analysis; CM, chylomicron; VLDL, very-low-density
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; DM, diabetes mellitus; CVD, cardiovascular and/or cerebrovascular disease.
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protein and TG synthesis [20,21]. These results suggest
that glucose absorption from dialysate activates the
endogenous pathway of lipoprotein metabolism in PD
patients, and that the exogenous pathway of lipopro-
tein metabolism may aggravate atherosclerosis though
the endogenous pathway.
There have been two reported routes through which
VLDL contributes to the progression of atherosclerosis,
namely, through intermediate density lipoprotein (IDL)
and small dense LDL [18,22]. The lipolysis and remodel-
ing of TG-rich VLDL produce IDL and LDL. Concerning
the IDL route to atherosclerosis, it has been reported
that human atherosclerosis plaques contain TG-rich lipo-
proteins [17]. In rabbits, TG-rich lipoprotein remnants
can penetrate the arterial wall [19]. However, in this study,
we were unable to evaluate the relationship between IDL
level and ABI because HPGPC does not enable the direct
measurement of IDL.
Under hypertriglyceridemia, the large TG-rich VLDL1
subfraction is mainly produced. Then, VLDL1 generates
the slowly metabolized, small dense LDL subspecies;
however, large and light LDLs, which are rapidly cleared
from the plasma, appear to result from the delipidation
of either IDL or VLDL2 [23]. In this study, the relation-
ships between TG level and the sizes of VLDL and LDL
particles were observed. The results of this study were
consistent with previous results and suggested that the
size of VLDL particles increases with an increase in serumTable 7 Correlations between sizes of lipoprotein particles an
Size of VLDL particles
r P
Total cholesterol level (mg/dl) −0.0746 0.67
CM cholesterol level (mg/dl) 0.861 0.0001*
VLDL cholesterol level (mg/dl) 0.569 0.0004*
LDL cholesterol level (mg/dl) −0.174 0.32
HDL cholesterol level (mg/dl) −0.381 0.024*
Triglyceride level (mg/dl) 0.701 0.0001*
Values are expressed as Pearson’s correlation coefficient and p values. *, p<0.05.
The relationships between sizes of lipoprotein particles and CM cholesterol and trig
Abbreviations: CM, chylomicron; VLDL, very-low-density lipoprotein; LDL, low-densit
F3-20, Fractions 3–20.TG level, and that the increase in large VLDL level may
induce small LDL particles.
It has been reported that the hepatic production of
VLDL1 is related to insulin resistance [24]. VLDL2 is not
related to insulin resistance. In PD patients, a high glucose
load absorbed from dialysate causes metabolic abnor-
malities. It has been reported that PD patients have a
higher homeostasis model assessment index than HD
patients [25]. It has also been reported that, after PD ini-
tiation, new-onset hypertriglyceridemia is observed among
PD patients [26,27]. These lines of evidence suggest that,
in PD patients, glucose absorption from dialysate induces
hypertriglyceridemia and insulin resistance followed by an
increase in VLDL1 and small dense LDL levels.
In this study, no relationships between the cholesterol
proportions in the LDL fractions and ABI were observed.
One of the reasons may be that most of the patients with
dyslipidemia were treated with a statin in this study. It has
been reported that statins decrease total LDL level [28].
The effect of statins on LDL may have masked the effect
of small dense LDL on atherosclerosis.
The size of HDL particles has been reported to be
affected by serum TG level [29]. An increased serum
TG level leads to a decrease in large HDL2 level and an
increase in small HDL3 level. Cholesterol ester transfer
protein transfers TG from TG-rich lipoproteins to HDL
[30]. Then, TG-enriched HDL is lipolyzed by hepatic
lipase. In this study, the size of HDL particles was nega-
tively associated with serum TG level and the cholesterold serum cholesterol levels of lipoproteins and TG levels
Size of LDL particles Size of HDL particles
r p r p
0.0922 0.60 −0.017 0.92
−0.414 0.014* −0.351 0.039*
−0.208 0.23 −0.368 0.030*
0.0746 0.67 −0.354 0.037*
0.259 0.13 0.734 0.0001*
−0.365 0.031* −0.455 0.006*
lyceride levels were evaluated by Spearman’s rank correlation coefficient.
y lipoprotein; HDL, high-density lipoprotein; r, Pearson’s correlation coefficient;
Table 8 Correlations between sizes of lipoprotein particles and cholesterol proportions in lipoprotein fractions
Size of VLDL particles Size of LDL particles Size of HDL particles
r p R P r p
CM 0.674 0.0001* −0.534 0.001* −0.310 0.070
F3 0.840 0.0001* −0.573 0.0003* −0.333 0.050
F4 0.878 0.0001* −0.563 0.0004* −0.348 0.041*
F5 0.795 0.0001* −0.277 0.11 −0.392 0.020*
F6 0.462 0.0052* −0.238 0.17 −0.398 0.018*
F7 −0.167 0.34 0.491 0.0028* −0.0650 0.71
F8 −0.584 0.0002* 0.757 0.0001* 0.0707 0.69
F9 −0.277 0.11 0.762 0.66 −0.457 0.0057*
F10 0.234 0.18 −0.610 0.0001* −0.793 0.0001*
F11 0.270 0.12 −0.602 0.0001* −0.799 0.0001*
F12 0.382 0.023* −0.648 0.0001* −0.473 0.0041*
F13 0.0473 0.79 −0.266 0.12 0.0679 0.70
F14 0.160 0.36 −0.134 0.44 0.177 0.31
F15 −0.290 0.092 0.310 0.070 0.826 0.0001*
F16 −0.419 0.012* 0.427 0.011* 0.911 0.0001*
F17 −0.433 0.0094* 0.183 0.29 0.575 0.0003*
F18 −0.0527 0.76 −0.408 0.015* −0.220 0.21
F19 −0.0149 0.93 −0.313 0.067 −0.239 0.17
F20 −0.0404 0.82 −0.255 0.14 0.129 0.46
Values are expressed as Pearson’s correlation coefficient and p values. *, p<0.05.
The relationships between sizes of lipoprotein particles and cholesterol proportions in CM were evaluated by Spearman’s rank correlation coefficient.
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serum TG level affects HDL metabolism in PD patients.
The results of this study showed that, among PD
patients with controlled LDL-C levels, VLDL was associ-
ated with atherosclerosis, and that a high serum TG level
atherogenically affected the size of lipoprotein particles.
LDL-C level has been used for the statin treatment goal
of dyslipidemia in ESRD patients. However, it has been
reported that statin treatment with lowering LDL-C level
has little or no effect on all-cause mortality, cardiovascular
mortality, or cardiovascular events in individuals receiv-
ing dialysis [31]. Additional markers to LDL-C level
and additional therapy with statins are needed to treat
dyslipidemia in ESRD patients. This study suggested that
VLDL-C level may be a useful candidate marker of athero-
sclerosis to treat dyslipidemia in ESRD patients.
It has been reported that PD patients with a high TG
level have a high risk of death [32]. A cohort study of PD
patients showed that ABI is associated with serum TG
level [6]. Therefore, lowering serum TG level can be a
target against atherosclerosis in PD patients after the
control of LDL-C level. Fibrate is often used to lower
serum TG level. Fenofibrate has been reported to reduce
serum TG level by 38% and small dense LDL-C level by
23% without changing LDL-C level, and to increase serum
HDL-C level by 14% in non-dialysis patients with type 2DM [28]. However, care should be taken to prevent the
development of adverse effects of fibrates such as rhabdo-
myolysis in PD patients treated with statins. An observa-
tional study of PD patients with DM showed that serum
LDL-C and TG levels decrease following an overnight
dwell with icodextrin [33]. A randomized controlled trial
showed a decreased serum TG level in diabetic PD pa-
tients treated with icodextrin [34]. The inhibition of
glucose absorption may be effective in lowering serum
TG level. More studies are required to evaluate the effects
of lowering serum TG level on the prevention of PAD and
atherosclerosis.
This study has several limitations. First, as with any
cross-sectional study, we were unable to examine the lon-
gitudinal changes in laboratory findings over time. Second,
this study involved 35 patients, which may be insufficient
for detecting the relationship between ABI and lipoprotein
fraction. Third, geographical and selection bias may have
been included in this study. Fourth, we did not investigate
the caloric intake such as diet or glucose load of dialysate.
We were also unable to adjust for the effects of caloric
intake on dyslipidemia. Fifth, we did not investigate in-
sulin resistance and thus were unable to evaluate the
effects of insulin resistance on lipoprotein fraction. Sixth,
because the DM patients were only 15 in this study, the
effect of antihyperglycemic drugs on dyslipidemia was not
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http://www.biomedcentral.com/1471-2369/14/212investigated. Seventh, most of the patients in this study had
anuria. We were unable to evaluate the effect of residual
renal function on lipid metabolism. Eighth, hypothyroidism
affects dyslipidemia in ESRD patients. However, we were
unable to carry out thyroid function tests.
Conclusions
This study showed that, among PD patients with controlled
LDL-C levels, VLDL was associated with atherosclerosis,
and that a high serum TG level had an atherogenic effect
on the size of lipoprotein particles. Because PD patients
tend to have high serum TG levels caused by glucose
absorption from dialysate, their endogenous pathway of
lipoprotein metabolism may be activated to produce
VLDL, which may lead to the progression of atheroscler-
osis. Lowering serum TG level may be an effective therapy
against atherosclerosis in PD patients after the control
of LDL-C level.
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